Development and validation of a blood‐based protein predictor of 20‐year dementia risk from middle age

In the US the number of individuals affected by dementia is expected to double by 2040. Thus, tools enabling identification of at‐risk individuals earlier in disease progression, or before disease onset, are vital. Proteomics‐driven risk stratification for dementia may enable the initiation of life‐planning and/or elicit changes in modifiable lifestyle‐related risk factors. Moreover, test results may facilitate enrichment of clinical trial enrollment, and ultimately as an aid in precision prescribing of preventative therapeutics. Therefore, we sought to develop and validate a blood‐based protein‐only predictor of 20‐year dementia risk from middle age.